PepGen Inc.
About PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$89.7M
- Total assets
- $173.9M
- Market cap
- $97.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $93.6M
- Operating income
- -$93.6M
- Income tax
- $49.0K
- Net income
- -$89.7M
- EPS (basic)
- $-2.12
- EPS (diluted)
- $-2.12
Balance sheet
- Total assets
- $173.9M
- Current assets
- $151.0M
- Total liabilities
- $26.5M
- Current liabilities
- $12.6M
- Shareholders’ equity
- $147.4M
Cash flow
- Operating cash flow
- -$81.6M
- Investing cash flow
- -$15.2M
- Financing cash flow
- $108.0M
- Net cash flow
- $11.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $97.5M
- EPS (diluted)
- $-2.12
- Shares outstanding
- 72.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 6, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $89.7M.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PepGen Inc..
Write a review
News about PepGen Inc.
News & sentiment via Polygon.io
